Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apremilast in AM-endotype Plaque Psoriasis
NCT03442088Phase 2Completed
- Sponsor
- University Hospitals Cleveland Medical Center
- Start
- Jun 2018
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of apremilast in plaque psoriasis, sponsored by University Hospitals Cleveland Medical Center. Primary endpoint: Change in Aberrant Inflammatory Profiles of Activated Blood Monocytes at Week 16. Started Jun 2018; status: completed.
02
Drugs
apremilast
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT03442088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03442088.